Two Is Better Than One in the Alzheimer’s Market
Wall Street Journal
The approval of Eli Lilly’s Alzheimer’s drug donanemab could help build momentum for Biogen’s struggling drug Leqembi.
https://www.wsj.com/articles/two-is-better-than-one-in-the-alzheimers-market-2b2e6aca